Clinical trial
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
NCT00839306 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
- Lead sponsor
- Eisai Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2008
- Completion date
- January 31, 2010
- Enrollment
- 240 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
gastroesophageal reflux disease (gerd)